Safety, tolerability and pharmacokinetics of GSK3923868 inhalation powder in healthy participants and stable asthmatics

Trial Identifier:	213497
Sponsor:	GlaxoSmithKline
Start Date:	March 2021
Primary Completion Date:	June 2022
Study Completion Date:	June 2022
Condition:	Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United Kingdom	Cambridge, United Kingdom, CB2 2GG

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.